|Day Low/High||10.23 / 10.49|
|52 Wk Low/High||7.12 / 11.85|
Opko Healthcare's CEO is chairman of an investment bank and number 134 on the Forbes 400 richest people in the world.
Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.
Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.
OPKO Health, Inc. (NASDAQ:OPK), announces the appointment of Benjamin D.
OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET).
Besides testing the S&P 500's 2100 level, we're also likely to see volume pick up as we head toward Friday's triple-witching expiration finale.
OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood, Esq.
OPKO Health, Inc. (NASDAQ:OPK) will present abstracts at the 55 th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) to be held in Paris, France on September 10-12, 2016.
OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11 th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9 th Annual...
OPKO Health, Inc. (NASDAQ: OPK), announces that it has completed its previously announced acquisition of Transition Therapeutics, Inc.
Cramer says SolarCity is too hard for him and he's losing patience with Cigna.
With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.
OPKO Health, Inc. (Nasdaq: OPK), announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc.
OPKO Health, Inc. (NYSE:OPK), is aware of a press release by Purcell Julie & Lefkowitz, LLP, a class action litigation firm, that it is investigating the Company for an alleged potential breach of fiduciary duty claim...
Opko Health (OPK) posted earnings and revenue that topped analysts' estimates for the 2016 second quarter following Monday's market close.
OPKO Health, Inc. (NYSE:OPK), reports financial and operating results for the three and six months ended June 30, 2016.
Cramer wants you to stick with Abbvie and says Cepheid is working.
Cramer has seen enough in this earnings season to come to some conclusions on what's working and what isn't.
OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three and six months ended June 30, 2016, after the close of the U.
Banking on its Rayaldee treatment, this once-quiet pharmaceutical company has stepped up its investor profile with its first analyst day and a recent move to Nasdaq.
OPKO Health, Inc. (NASDAQ:OPK) and Transition Therapeutics Inc.